TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Correlation strength for treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sRAGE levels in seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of overall adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of antibiotics exposure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of antibiotic-associated adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cure rates on day 28
Endpoint domain: Mortality/survival
Primary endpoint: Cure rates on day 63
Endpoint domain: Mortality/survival
Primary endpoint: Clearing of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intensity of electrically evoked pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mechanical pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Environmental radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cmax of 3-hydroxyquinine metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of facial laxity and wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of hospital admissions due to gastrointestinal disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Bowel obstruction admissions
Endpoint domain: Adverse events/effects
Primary endpoint: disability outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or oxygen dependency at 36 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Pneumothorax rates
Endpoint domain: Adverse events/effects
Primary endpoint: Median duration of ventilation for survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Delay in ETT cuff pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of ventral epidural spreading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total absorption of hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent CS-DH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median touch threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct answers in discrimination between 2 levels of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correctly located touch in trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Importance of IOP-lowering for preserving vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to continue using bimatoprost
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cortisol responses to mCPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol responses to yohimbine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pulse responses to yohimbine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma ET-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet inhibition post-cangrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of cardiovascular death, nonfatal MI, and nonfatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: urgent target vessel revascularization (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: any target vessel revascularization (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death or nonfatal AMI
Endpoint domain: Mortality/survival
Primary endpoint: Feeding skill score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral motor dysfunction (OMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Heightened neural positive prediction error (δ+) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean examination quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional interventions required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of uneventful recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Degree of contrast enhancement of the cochlea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median weight loss after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of feeling of hunger after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median decrease in BMI after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ankle sprain recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: central anticholinergic‐like adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mean change in ADAS‐Cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Catheter-related colonization
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported tonic craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CT dose index (CTDI) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total dose of contrast material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: injection rate for contrast material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of incontinence subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in ISGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of paclitaxel (C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue angiogenesis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum angiogenic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUClast) for troglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of troglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Half-life of the sulphate conjugate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: General health index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urinary symptom index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GE behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary fat intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in clinical outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment course duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: resolution of delayed gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptoms of radiomucositis, pain, and nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 13C‐methacetin cumulative oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mercury concentration in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence to therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CBV (Cerebral Blood Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NFL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolved to frailty
Endpoint domain: Mortality/survival
Primary endpoint: Outdoors walking hour per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak and thrombin formation velocity (VELINDEX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: F1 + 2 and thrombin/antithrombin complex (TAT) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitality scores over time
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Symptomatic benefit from antireflux surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient satisfaction with overall outcome of the operation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adjunctive treatment options for youth MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local recurrence (LR) after conservative surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: instantaneous TNSSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: instantaneous TOSSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinoconjunctivitis Quality of Life Questionnaire total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: proportion of referred patients at elevated risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of extrapyramidal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative ileus incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bleeding of gastroduodenal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time taken for hepaticojejunostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Insufficiency rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative frequency of diagnosed eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative frequency of skin prick sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of atopic eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: WOMAC functional impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum plantar pressure during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum plantar pressure during jogging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plantar pressure during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plantar pressure during jogging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence to CRC screening guidelines
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: log MMP1/TIMP1 ratio levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net LV twist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spatial memory and visual-motor integration scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mean OAB‐q HRQoL total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of bracket fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in numeric rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity with study lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to UC separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of nosocomial UC colonization
Endpoint domain: Adverse events/effects
Primary endpoint: push-out strengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent absorption of D‐tagatose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak-flow variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: illness severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of bleeding and/or spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median age at menarche
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Frequency of reply letters addressing patients' questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to discuss reproductive health with healthcare providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge retention regarding reproductive health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of sexual activity and abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: functional capacity measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of gel and applicator
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of grade 4 anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of confirmed response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of venous thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of postoperative fistulas
Endpoint domain: Adverse events/effects
Primary endpoint: one-year quit rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of UL distal spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Postural sway (area of center of pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic posturography overall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean serum level of somatostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual provisional cement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic progression-free survival (rPFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) as measured by SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: OPN levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tizanidine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to plasma concentrations
Endpoint domain: Adverse events/effects
Primary endpoint: relapse/recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in post-operative swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed 25ft walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Ramsay sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flow time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC0-20 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death or major disability after acute ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: times of interrupting enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of target feeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in plasma sitosterol and campesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Asymptomatic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort or pain along the vein used for infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative functional urethral length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reconnection/DC per vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Repeated procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PPD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry mouth severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score for comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of heavy menstrual bleeding (HMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events associated with treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Total reduction in migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in moderate/severe headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days using acute medication for headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL anti-inflammation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitric oxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ulcer granulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma K decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe side effects at 1 month
Endpoint domain: Adverse events/effects
Primary endpoint: survival to hospital discharge with mRS ≤3
Endpoint domain: Mortality/survival
Primary endpoint: Achievement of TIMI grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of TMP grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: discontinuation rate due to adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: hemodynamic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes